secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0001628280-24-019607
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept Q1 revenue up 39% to $146.8M; raises FY2024 guidance to $620-650M
-------------------------------------------------------------------------

- Revenue $146.8M (+39% YoY); diluted EPS $0.25 vs $0.14; net income $27.8M.
- 2024 revenue guidance raised to $620-650M from $600-630M.
- Cash and investments $451.0M at March 31, 2024.
- GRACE open-label phase showed significant improvements; NDA for relacorilant in Cushing's expected this quarter.
- Enrollment completed in GRADIENT, CATALYST, ROSELLA, DAZALS; data expected by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000162828024019607/0001628280-24-019607-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000162828024019607/cort-20240501.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-019607

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer